中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (12): 1048-1056.doi: 10.35541/cjd.20210561
中国康复医学会皮肤病康复专业委员会 中华医学会皮肤性病学分会光动力治疗研究中心 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组
收稿日期:2021-08-04
修回日期:2021-09-25
发布日期:2021-12-01
通讯作者:
王秀丽；顾恒；陈翔
E-mail:wangxiuli_1400023@tongji.edu.cn;guheng@aliyun.com; chenxiangck@126.com
Chinese Association of Rehabilitation Dermatology; Photodynamic Therapy Research Center, Chinese Society of Dermatology; Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment
Received:2021-08-04
Revised:2021-09-25
Published:2021-12-01
Contact:
Wang Xiuli; Gu Heng；Chen Xiang
E-mail:wangxiuli_1400023@tongji.edu.cn;guheng@aliyun.com; chenxiangck@126.com
摘要： 【摘要】 光线性角化病是一种慢性进行性癌前病变，可进展为皮肤鳞状细胞癌。随着中国患病人数逐渐增多，亟须建立合适的诊断及治疗规范。中国康复医学会皮肤病康复专业委员会、中华医学会皮肤性病学分会联合中国医学装备协会皮肤病与皮肤美容分会组织光线性角化病相关领域部分专家，在国内外文献数据、国际指南和专家临床经验的基础上，结合我国诊疗现状，制定中国光线性角化病临床诊疗专家共识。本共识从光线性角化病的流行病学、发病因素及临床转归、临床表现及分级、诊断及鉴别诊断、治疗策略和患者教育管理等方面进行阐述，诊断方面包含了皮肤镜、反射式共聚焦显微镜和皮肤病理等手段，治疗策略涵盖了常见局部治疗和系统治疗方法，局部治疗包括光动力治疗、外用药物、物理治疗和手术切除，且按照证据等级给予推荐级别，为皮肤科医师诊疗工作提供参考。
中国康复医学会皮肤病康复专业委员会 中华医学会皮肤性病学分会光动力治疗研究中心 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 中国光线性角化病临床诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021,54(12):1048-1056. doi:10.35541/cjd.20210561
Chinese Association of Rehabilitation Dermatology, Photodynamic Therapy Research Center, Chinese Society of Dermatology, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Expert consensus on clinical diagnosis and treatment of actinic keratosis in China（2021）[J]. Chinese Journal of Dermatology, 2021, 54(12): 1048-1056.doi:10.35541/cjd.20210561
| ［1］ | Ratushny V, Gober MD, Hick R, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma［J］. J Clin Invest, 2012,122（2）:464⁃472. doi: 10.1172/JCI57415. |
| ［2］ | Olsen EA, Abernethy ML, Kulp⁃Shorten C, et al. A double⁃blind, vehicle⁃controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck［J］. J Am Acad Dermatol, 1991,24（5 Pt 1）:738⁃743. doi: 10.1016/0190⁃9622（91）70113⁃g. |
| ［3］ | Lee JH, Kim YH, Han KD, et al. Incidence of actinic keratosis and risk of skin cancer in subjects with actinic keratosis: a population⁃based cohort study［J］. Acta Derm Venereol, 2018,98（3）:382⁃383. doi: 10.2340/00015555⁃2854. |
| ［4］ | 涂庆峰, 吕婷, 赖永贤, 等. 上海市某社区老年人皮肤肿瘤流行病学研究［J］. 老年医学与保健, 2013,19（3）:142⁃145,148. doi: 10.3969/j.issn.1008⁃8296.2013⁃05. |
| ［5］ | Zhao Y, Li CY, Wen CM, et al. The prevalence of actinic keratosis in patients visiting dermatologists in two hospitals in China［J］. Br J Dermatol, 2016,174（5）:1005⁃1010. doi: 10.1111/ bjd.14344. |
| ［6］ | Ferrándiz C, Plazas MJ, Sabaté M, et al. Prevalence of actinic keratosis among dermatology outpatients in Spain［J］. Actas Dermosifiliogr, 2016,107（8）:674⁃680. doi: 10.1016/j.ad.2016. 05.016. |
| ［7］ | Fargnoli MC, Altomare G, Benati E, et al. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics［J］. Eur J Dermatol, 2017,27（6）:599⁃608. doi: 10.1684/ejd.2017.3126. |
| ［8］ | Reinehr C, Bakos RM. Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects［J］. An Bras Dermatol, 2019,94（6）:637⁃657. doi: 10.1016/j.abd.2019.10.004. |
| ［9］ | Butani AK, Arbesfeld DM, Schwartz RA. Premalignant and early squamous cell carcinoma［J］. Clin Plast Surg, 2005,32（2）:223⁃235. doi: 10.1016/j.cps.2004.11.001. |
| ［10］ | Engel A, Johnson ML, Haynes SG. Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971⁃1974［J］. Arch Dermatol, 1988,124（1）:72⁃79. |
| ［11］ | de Oliveira E, da Motta V, Pantoja PC, et al. Actinic keratosis ⁃ review for clinical practice［J］. Int J Dermatol, 2019,58（4）:400⁃407. doi: 10.1111/ijd.14147. |
| ［12］ | Flohil SC, van der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study［J］. J Invest Dermatol, 2013,133（8）:1971⁃1978. doi: 10.1038/jid.2013.134. |
| ［13］ | Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective［J］. Dermatol Ther （Heidelb）, 2015,5（1）:19⁃35. doi:10.1007/s13555⁃ 015⁃0070⁃9. |
| ［14］ | Ulrich C, Jürgensen JS, Degen A, et al. Prevention of non⁃melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case⁃control study［J］. Br J Dermatol, 2009,161 Suppl 3:78⁃84. doi: 10.1111/j.1365⁃2133.2009.09453.x. |
| ［15］ | Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial［J］. Cancer, 2009,115（11）:2523⁃2530. doi: 10.1002/cncr.24284. |
| ［16］ | Dodson JM, DeSpain J, Hewett JE, et al. Malignant potential of actinic keratoses and the controversy over treatment. A patient⁃oriented perspective［J］. Arch Dermatol, 1991,127（7）:1029⁃1031. |
| ［17］ | Lopes ML, Silva Júnior FL, Lima KC, et al. Clinicopathological profile and management of 161 cases of actinic cheilitis［J］. An Bras Dermatol, 2015,90（4）:505⁃512. doi: 10.1590/abd1806⁃4841.20153848. |
| ［18］ | de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists′ guidelines for the care of patients with actinic keratosis 2017［J］. Br J Dermatol, 2017,176（1）:20⁃43. doi: 10.1111/bjd.15107. |
| ［19］ | Vatve M, Ortonne JP, Birch⁃Machin MA, et al. Management of field change in actinic keratosis［J］. Br J Dermatol, 2007,157 Suppl 2:21⁃24. doi: 10.1111/j.1365⁃2133.2007.08268.x. |
| ［20］ | Huerta⁃Brogeras M, Olmos O, Borbujo J, et al. Validation of dermoscopy as a real⁃time noninvasive diagnostic imaging technique for actinic keratosis［J］. Arch Dermatol, 2012,148（10）:1159⁃1164. doi: 10.1001/archdermatol.2012.1060. |
| ［21］ | Yang X, Hu C, Wen L, et al. Dermoscopic monitoring for treatment and follow⁃up of actinic keratosis with 5⁃aminolaevulinic acid photodynamic therapy［J］. Technology in Cancer Research & Treatment, 2018, 17（3）: 153 303381882009. doi:10.1177/1533033818820091. |
| ［22］ | Zalaudek I, Piana S, Moscarella E, et al. Morphologic grading and treatment of facial actinic keratosis［J］. Clin Dermatol, 2014,32（1）:80⁃87. doi: 10.1016/j.clindermatol.2013.05.028. |
| ［23］ | 中国医疗保健国际交流促进会皮肤科分会皮肤影像学组, 中华医学会皮肤性病学分会皮肤病数字化诊断亚学组, 中国中西医结合学会皮肤性病专业委员会皮肤影像学组, 等. 鳞状细胞肿瘤皮肤镜特征专家共识（2017）［J］. 中华皮肤科杂志, 2018,51（2）:87⁃91. doi: 10.3760/cma.j.issn.0412⁃4030.2018.02. 001. |
| ［24］ | Papageorgiou C, Lallas A, Manoli SM, et al. Evaluation of dermatoscopic criteria for early detection of squamous cell carcinoma arising on an actinic keratosis［J］. J Am Acad Dermatol, 2021:S0190⁃9622（21）00760⁃X. doi: 10.1016/j.jaad.2021.03.111. |
| ［25］ | Jin Q, Li W, Wu W, et al. Assessment of 5⁃aminolaevulinic acid photodynamic therapy （ALA⁃PDT） in Chinese patients with actinic keratosis: correlation of dermoscopic features with histopathology［J］. Australas J Dermatol, 2020,61（3）:e339⁃e343. doi: 10.1111/ajd.13289. |
| ［26］ | Prow TW, Tan JM, Pellacani G. Reflectance confocal microscopy: hallmarks of keratinocyte cancer and its precursors［J］. Curr Probl Dermatol, 2015,46:85⁃94. doi: 10.1159/00036 6541. |
| ［27］ | 刘峰, 刘刚, 徐丽敏, 等. 运用共聚焦激光扫描显微镜在术前测定日光性角化病边界的效果分析［J］. 中国皮肤性病学杂志, 2014,28（3）:263⁃265+268. |
| ［28］ | Nguyen KP, Peppelman M, Hoogedoorn L, et al. The current role of in vivo reflectance confocal microscopy within the continuum of actinic keratosis and squamous cell carcinoma: a systematic review［J］. Eur J Dermatol, 2016,26（6）:549⁃565. doi: 10.1684/ejd.2016.2872. |
| ［29］ | 吴秀娟, 向芳, 赵宗峰, 等. 反射式共聚焦扫描显微镜在日光性角化病诊断中的应用［J］. 中国麻风皮肤病杂志, 2016,32（5）:267⁃269. |
| ［30］ | Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma （"actinic keratosis"）［J］. J Am Acad Dermatol, 2000,42（1 Pt 2）:11⁃17. doi: 10.1067/mjd.2000.103344. |
| ［31］ | McKee P, Calonje E, Granter S, et al. 皮肤病理学: 与临床的联系［M］. 朱学骏, 孙建方, 译. 3版. 北京: 北京大学医学出版社, 2007:1187⁃1192. |
| ［32］ | Roewert⁃Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic （solar） keratosis ⁃ an update［J］. Br J Dermatol, 2007,157 Suppl 2:18⁃20. doi: 10.1111/j.1365⁃2133. 2007.08267.x. |
| ［33］ | Wong TH, Morton CA, Collier N, et al. British Association of Dermatologists and British Photodermatology Group guidelines for topical photodynamic therapy 2018［J］. Br J Dermatol, 2019,180（4）:730⁃739. doi: 10.1111/bjd.17309. |
| ［34］ | Szeimies RM, Radny P, Sebastian M, et al. Photodynamic therapy with BF⁃200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double⁃blind, placebo⁃controlled phase III study［J］. Br J Dermatol, 2010,163（2）:386⁃394. doi: 10.1111/j.1365⁃2133.2010.09873.x. |
| ［35］ | 中华医学会皮肤性病学分会光动力治疗研究中心, 中国康复医学会皮肤病康复专业委员会, 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 氨基酮戊酸光动力疗法皮肤科临床应用指南（2021版）［J］. 中华皮肤科杂志, 2021,54（1）:1⁃9. doi: 10.35541/cjd.20200731. |
| ［36］ | Zhu L, Wang P, Zhang G, et al. Conventional versus daylight photodynamic therapy for actinic keratosis: a randomized and prospective study in China［J］. Photodiagnosis Photodyn Ther, 2018,24:366⁃371. doi: 10.1016/j.pdpdt.2018.10.010. |
| ［37］ | Cai H, Wang YX, Sun P, et al. Photodynamic therapy for facial actinic keratosis: a clinical and histological study in Chinese patients［J］. Photodiagnosis Photodyn Ther, 2013,10（3）:260⁃265. doi: 10.1016/j.pdpdt.2012.12.003. |
| ［38］ | Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12⁃month follow up［J］. Br J Dermatol, 2006,155（6）:1262⁃1269. doi: 10.1111/j.1365⁃2133.2006.07520.x. |
| ［39］ | Jansen M, Kessels J, Nelemans PJ, et al. Randomized trial of four treatment approaches for actinic keratosis［J］. N Engl J Med, 2019,380（10）:935⁃946. doi: 10.1056/NEJMoa1811850. |
| ［40］ | Zhang L, Zhao Z, Wang P, et al. Long⁃term improvement on photoaging after ALA photodynamic therapy for actinic keratosis: a retrospective study［J］. Photodiagnosis Photodyn Ther, 2021,33:102181. doi: 10.1016/j.pdpdt.2021.102181. |
| ［41］ | Chen J, Zhang Y, Wang P, et al. Plum⁃blossom needling promoted PpIX fluorescence intensity from 5⁃aminolevulinic acid in porcine skin model and patients with actnic keratosis［J］. Photodiagnosis Photodyn Ther, 2016,15:182⁃190. doi: 10.1016/j.pdpdt.2016.06.012. |
| ［42］ | Zheng Z, Zhang LL, Shi L, et al. What is the most relevent factor causing pain during ALA⁃PDT? A multi⁃center, open clinical pain score research trial of actinic keratosis, acne and condylomata acuminata［J］. Photodiagnosis Photodyn Ther, 2019,26:73⁃78. doi: 10.1016/j.pdpdt.2019.03.001. |
| ［43］ | Ibbotson SH, Wong TH, Morton CA, et al. Adverse effects of topical photodynamic therapy: a consensus review and approach to management［J］. Br J Dermatol, 2019,180（4）:715⁃729. doi: 10.1111/bjd.17131. |
| ［44］ | Dréno B, Amici JM, Basset⁃Seguin N, et al. Management of actinic keratosis: a practical report and treatment algorithm from AKTeam™ expert clinicians［J］. J Eur Acad Dermatol Venereol, 2014,28（9）:1141⁃1149. doi: 10.1111/jdv.12434. |
| ［45］ | Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double⁃blind, vehicle⁃controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses［J］. Arch Dermatol, 2002,138（11）:1498⁃1502. doi: 10.1001/archderm.138. 11.1498. |
| ［46］ | Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double⁃blind, vehicle⁃controlled, clinical trial with histology［J］. J Am Acad Dermatol, 2004,51（4）:547⁃555. doi: 10.1016/j.jaad.2004.02.022. |
| ［47］ | Swanson N, Smith CC, Kaur M, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double⁃blind, placebo⁃controlled studies［J］. J Drugs Dermatol, 2013,12（11）:1278⁃1282. |
| ［48］ | 王宏伟, 王秀丽, 过明霞. 外用咪喹莫特乳膏致局限型白癜风二例［J］. 中华皮肤科杂志, 2006,39（10）:613. doi: 10.3760/j.issn:0412⁃4030.2006.10.029. |
| ［49］ | Segatto MM, Dornelles SI, Silveira VB, et al. Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5⁃fluorouracil［J］. An Bras Dermatol, 2013,88（5）:732⁃738. doi: 10.1590/abd1806⁃4841.20132083. |
| ［50］ | Dianzani C, Conforti C, Giuffrida R, et al. Current therapies for actinic keratosis［J］. Int J Dermatol, 2020,59（6）:677⁃684. doi: 10.1111/ijd.14767. |
| ［51］ | Werner RN, Jacobs A, Rosumeck S, et al. Methods and results report ⁃ evidence and consensus⁃based （S3） guidelines for the treatment of actinic keratosis ⁃International League of Dermatological Societies in cooperation with the European Dermatology Forum［J］. J Eur Acad Dermatol Venereol, 2015,29（11）:e1⁃e66. doi: 10.1111/jdv.13179. |
| ［52］ | Walker JL, Siegel JA, Sachar M, et al. 5⁃Fluorouracil for actinic keratosis treatment and chemoprevention: a randomized controlled trial［J］. J Invest Dermatol, 2017,137（6）:1367⁃1370. doi: 10.1016/j.jid.2016.12.029. |
| ［53］ | Stough D, Bucko AD, Vamvakias G, et al. Fluorouracil cream 0.5% for actinic keratoses on multiple body sites: an 18⁃month open⁃label study［J］. Cutis, 2010,85（5）:267⁃273. |
| ［54］ | Hoover WD 3rd, Jorizzo JL, Clark AR, et al. Efficacy of cryosurgery and 5⁃fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis［J］. Cutis, 2014,94（5）:255⁃259. |
| ［55］ | Stockfleth E, von Kiedrowski R, Dominicus R, et al. Efficacy and safety of 5⁃fluorouracil 0.5%/salicylic acid 10% in the field⁃directed treatment of actinic keratosis: a phase iii, randomized, double⁃blind, vehicle⁃controlled trial［J］. Dermatol Ther （Heidelb）, 2017,7（1）:81⁃96. doi: 10.1007/s13555⁃016⁃0161⁃2. |
| ［56］ | Ulrich M, Reinhold U, Falqués M, et al. Use of reflectance confocal microscopy to evaluate 5⁃fluorouracil 0.5%/salicylic acid 10% in the field⁃directed treatment of subclinical lesions of actinic keratosis: subanalysis of a Phase III, randomized, double⁃blind, vehicle⁃controlled trial［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:390⁃396. doi: 10.1111/jdv.14611. |
| ［57］ | Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel［J］. Br J Dermatol, 2002,146（1）:94⁃100. doi: 10.1046/j.1365⁃2133.2002. 04561.x. |
| ［58］ | Akarsu S, Aktan S, Atahan A, et al. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses［J］. Clin Exp Dermatol, 2011,36（5）:479⁃484. doi: 10.1111/j.1365⁃2230.2010.03999.x. |
| ［59］ | Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial［J］. J Am Acad Dermatol, 2003,49（1）:83⁃90. doi: 10.1067/mjd.2003.451. |
| ［60］ | Ianhez M, Pinto SA, Miot HA, et al. A randomized, open, controlled trial of tretinoin 0.05% cream vs. low⁃dose oral isotretinoin for the treatment of field cancerization［J］. Int J Dermatol, 2019,58（3）:365⁃373. doi: 10.1111/ijd.14363. |
| ［61］ | Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses［J］. Int J Dermatol, 2004,43（9）:687⁃692. doi: 10.1111/j.1365⁃4632.2004. 02056.x. |
| ［62］ | Zane C, Facchinetti E, Rossi MT, et al. Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial［J］. Br J Dermatol, 2014,170（5）:1114⁃1121. doi: 10.1111/bjd. 12847. |
| ［63］ | Ianhez M, Fleury LF Jr, Miot HA, et al. Retinoids for prevention and treatment of actinic keratosis［J］. An Bras Dermatol, 2013,88（4）:585⁃593. doi: 10.1590/abd1806⁃4841.20131803. |
| ［64］ | de Sévaux RG, Smit JV, de Jong EM, et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin［J］. J Am Acad Dermatol, 2003,49（3）:407⁃412. doi: 10.1067/s0190⁃9622（03）01831⁃0. |
| ［65］ | 中国医师协会皮肤科医师分会皮肤美容事业发展工作委员会. 皮肤防晒专家共识（2017）［J］. 中华皮肤科杂志, 2017,50（5）:316⁃320. doi:10.3760/cma.j.issn.0412⁃4030.2017.05.002. |
| [1] | 《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195. |
| [2] | 吕玲 吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279. |
| [3] | 李锁 向睿宇 李志量 荆可 王媛 张寒梅 冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237. |
| [4] | 王媛 余美文 向睿宇 李锁 李志量 荆可 张寒梅 冯素英. 盐裂皮肤-间接免疫荧光方法优化及在大疱性类天疱疮抗体检测中的应用[J]. 中华皮肤科杂志, 2022, 55(1): 12-15. |
| [5] | 张莹 甘璐 李思琪 李颜 宋昊 邵雪宝 张韡 徐秀莲 姜祎群 曾学思 陈浩 孙建方. 伴大细胞转化的蕈样肉芽肿24例临床病理及免疫表型分析[J]. 中华皮肤科杂志, 2022, 55(1): 20-26. |
| [6] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识（2022）[J]. 中华皮肤科杂志, 2022, 55(1): 1-11. |
| [7] | 王小燕, 张嘉文, 刘韵祎, 刘乙萱, 姜沛彧, 李敏, 陶梦, 许阳. 玫瑰痤疮的皮肤影像学和无创检测技术相关进展[J]. 中华皮肤科杂志, 2022, 0(1): 20200939-e20200939. |
| [8] | 程必红, 窦侠. 慢性痒疹的诊断及分型新进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210130-e20210130. |
| [9] | 王逸飞 耿怡 缪秋菊 宋昊 徐秀莲 孙建方. 黏蛋白痣10例临床病理分析[J]. 中华皮肤科杂志, 2021, 54(9): 804-807. |
| [10] | 邱月棨 付思祺 罗帅寒天 李亚萍 张桂英. 2020年雄激素性脱发的研究进展[J]. 中华皮肤科杂志, 2021, 54(9): 835-838. |
| [11] | 中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770. |
| [12] | 中华医学会皮肤性病学分会皮肤肿瘤研究中心 中国医师协会皮肤科医师分会皮肤肿瘤学组. 皮肤基底细胞癌诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(9): 757-764. |
| [13] | 宋歌 梁官钊 张美洁 董嘉琤 刘维达. 毳毛癣的临床诊治进展[J]. 中华皮肤科杂志, 2021, 54(8): 741-743. |
| [14] | 王大光 蒋佳怡. 几种甲病诊疗的思考[J]. 中华皮肤科杂志, 2021, 54(8): 733-737. |
| [15] | 宋志强 顾恒. 加强皮炎湿疹类疾病诊断术语的规范化[J]. 中华皮肤科杂志, 2021, 54(8): 665-667. |
|
